Literature DB >> 6401585

Analysis of contaminants in factor VIII preparations administered to patients with hemophilia.

G A Rock, G Farrah, G Rozon, R K Smiley, R Cole, D Villeneuve, P Tittley.   

Abstract

Cryoprecipitate and the more purified factor VIII concentrates are all heterogeneous preparations that contain not only a high concentration of factor VIII but also various other materials, some of which might be injurious, causing liver damage after long-term exposure. The efficiency of three standard cryoprecipitate filters, two microaggregate filters and the appropriate factor VIII concentrate filters in reducing the amount of particulate matter delivered to the patient was assessed. Filtration of cryoprecipitate through the standard filters removed less than 20% of the contaminating microaggregates and very few of the large number of intact platelets, although the total dose of factor VIII was delivered. Microaggregate filters were no better in reducing the platelet contamination, although the total number of particles delivered was halved. However, 25% of the factor VIII was retained in the bed volume of the filter. The concentrate preparations also contained significant amounts of particulate matter that was unrelated to factor VIII and was not removed following filtration through the designated filter. These findings indicate that a new filter should be developed for administration of factor VIII concentrate that would remove the particulate matter while delivering all of the factor VIII to the patient.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6401585      PMCID: PMC1875030     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  12 in total

1.  Studies on the hepatic effects of orally administered di-)2-ethylhexyl) phthalate in the rat.

Authors:  B G Lake; S D Gangolli; P Grasso; A G Lloyd
Journal:  Toxicol Appl Pharmacol       Date:  1975-05       Impact factor: 4.219

2.  The effects of temperature variations on cryoprecipitate.

Authors:  G A Rock; P Tittley
Journal:  Transfusion       Date:  1979 Jan-Feb       Impact factor: 3.157

3.  Jaundice and hepatitis B antigen-antibody in hemophilia.

Authors:  J H Lewis; N G Maxwell; J M Brandon
Journal:  Transfusion       Date:  1974 May-Jun       Impact factor: 3.157

4.  Hemophilia, hepatitis and HAA.

Authors:  J H Lewis
Journal:  Vox Sang       Date:  1970 Sep-Oct       Impact factor: 2.144

5.  Percutaneous liver biopsy and chronic liver disease in haemophiliacs.

Authors:  F E Preston; D R Triger; J C Underwood; G Bardhan; V E Mitchell; R M Stewart; E K Blackburn
Journal:  Lancet       Date:  1978-09-16       Impact factor: 79.321

6.  The in vitro hydrolysis of di-(2-ethylhexyl) phthalate by rat tissues.

Authors:  J E Carter; D B Roll; R V Petersen
Journal:  Drug Metab Dispos       Date:  1974 Jul-Aug       Impact factor: 3.922

7.  Filtration of cryoprecipitate: a microscopic assessment of filter depostion.

Authors:  M J Inwood; J D Barr; B A Warren; W J Chauvin
Journal:  Transfusion       Date:  1978 Nov-Dec       Impact factor: 3.157

8.  Metabolic changes during platelet storage.

Authors:  G Rock; A Figueredo
Journal:  Transfusion       Date:  1976 Nov-Dec       Impact factor: 3.157

9.  Recurrent acute hepatitis following the use of factor VIII concentrates.

Authors:  T J Myers; C L Tembrevilla-Zubiri; A U Klatsky; F R Rickles
Journal:  Blood       Date:  1980-05       Impact factor: 22.113

10.  The accumulation of mono-2-ethylhexylphthalate (MEHP) during storage of whole blood and plasma.

Authors:  G Rock; V E Secours; C A Franklin; I Chu; D C Villeneuve
Journal:  Transfusion       Date:  1978 Sep-Oct       Impact factor: 3.157

View more
  3 in total

1.  Leachables from saline-containing IV bags can alter therapeutic protein properties.

Authors:  Judy Y Chang; Nina J Xiao; Min Zhu; Jennifer Zhang; Ed Hoff; Stephen J Russell; Viswanatham Katta; Steven J Shire
Journal:  Pharm Res       Date:  2010-06-30       Impact factor: 4.200

2.  Distribution of di(2-ethylhexyl) phthalate and products in blood and blood components.

Authors:  G Rock; R S Labow; M Tocchi
Journal:  Environ Health Perspect       Date:  1986-03       Impact factor: 9.031

3.  Inhibition of human platelet phospholipase A2 by mono(2-ethylhexyl)phthalate.

Authors:  R S Labow; E Meek; G A Adams; G Rock
Journal:  Environ Health Perspect       Date:  1988-06       Impact factor: 9.031

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.